Figure 2From: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study Comparisons of disease control rate (partial response or stable disease reported by tumor response assessment) between platinum/pemetrexed and the other four studied platinum-based doublets in the propensity score matched patients. Back to article page